Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Antithrombotic Therapy in Patients with Atrial Fibrillation after Myocardial Infarction: Clinical Guidelines and Actual Practice

https://doi.org/10.20996/1819-6446-2018-14-6-858-863

Full Text:

Abstract

Aim. To study the frequency of oral anticoagulants (ОАС) prescription for patients with atrial fibrillation (AF) after myocardial infarction (MI). Material and methods. The study includes 106 patients (60 men, 55.6%) with a previously established diagnosis of AF, who were on hospital treatment in the period 2016-2017 years in one of the university hospitals of the city and having at the time of discharge from the hospital the final diagnosis of МI. The median age was 70.0 (61.0;78.0) years. Patients with the first and only paroxysm of AF were excluded from the analysis and all further calculations were performed for 104 patients. In 64 (60.2%) of cases, AF was presented by paroxysmal form, while in 2 (1.9%) cases this paroxysm was the first and only, in 20 (18.9%) cases – persistent AF and in 20 (18.9%) – pernanent. Results. While assessing the risk of thromboembolic complications on the CHA2DS2-VASc scale, the median score for all patients was 5.0 (4.0;6.0) points. While assessing the risk of hemorrhagic complications on the HAS-BLED scale, the median score for all patients was 2.0 (2.0;3.0) points. HAS-BLED≤2 value had 71 (68.3%) patients, HAS-BLED≥3 – 33 (31.7%). Only one antiplatelet agent was prescribed to 4 (3.8%) patients. Aspirin was the only antiplatelet agent in 3 cases and clopidogrel – in one case. In 80 (76.9%) cases, patients were prescribed dual antiplatelet therapy, in 17 (16.3%) – ОАС therapy, among which 7 (6.7%) cases – a triple antithrombotic therapy (ATT), 9 (8.7%) cases – a double ATT (ОАС+ antiplatelet agent) and 1 (1.0%) case – a monotherapy. Among all cases of OAC prescription warfarin was prescribed in 11 (64.7%) cases and rivaroxaban – in 6 (35.3%). Conclusion. In real clinical practice, the prescription or refusal of ОАС occurs without taking into account the risk of thromboembolic and hemorrhagic complications according to appropriate scales.

About the Authors

K. G. Pereverzeva
Ryazan State Medical University named after Academician I.P. Pavlov; Ryazan Regional Clinical Cardiology Dispensary
Russian Federation
MD, PhD, Assistant, Chair of Hospital Therapy, Ryazan State Medical University named after Academician I.P. Pavlov; Infarction Department, Ryazan Regional Clinical Cardiology Dispensary


S. S. Yakushin
Ryazan State Medical University named after Academician I.P. Pavlov
Russian Federation
MD, PhD, Professor, Head of Chair of Hospital Therapy


A. E. Pripadcheva
Ryazan State Medical University named after Academician I.P. Pavlov
Russian Federation
6th Year Student, Medical Faculty


N. P. Agaltsova
Ryazan Regional Clinical Cardiology Dispensary
Russian Federation
MD, Cardiologist, Infarction Department


References

1. Yakushin S.S., Nikulina N.N., Seleznev S.V. Myocardial infarction. 2nd edition. Moscow: GEOTARMedia; 2018. (In Russ.)

2. Schmitt J., Duray G., Gersh B.J., et al. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J. 2009;(30):1038-45. doi:10.1093/eurheartj/ehn579.

3. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77. doi:10.1093/eurheartj/ehx393.

4. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719-47. doi:10.1093/eurheartj/ehs253.

5. Heidbuchel H., Verhamme P., Alings M., et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;(15):625-51. doi:10.1093/europace/eut083.

6. Wijns W., Kolh P., Danchin N. et al. Guidelines on myocardial revascularization. Eur Heart J. 2010;(31):2501-55. doi:10.1093/eurheartj/ehq277.

7. Connolly S., Pogue J., Hart R. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet. 2006;(367):1903-12. doi:10.1016/S0140-6736(06)68845-4.

8. Eniseeva E.S. Double and triple antithrombotic therapy in atrial fibrillation and acute coronary syndrome. Sibirskij Medicinskij Zhurnal (Irkutsk). 2016;141(2):18-22. (In Russ.)

9. Neumann F.J., Sousa-Uva M., Ahlsson A., et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2018 Aug 25. doi:10.1093/eurheartj/ehy394. [Epub ahead of print]

10. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-2962. doi:10.1093/eurheartj/ehw210.

11. Novikova N.A., Shilova A.S. The specifics of prescribing triple antitrombotic therapy with rivaroxaban in patients with atrial fibrillation after coronary stenting. Aterotromboz. 2017;(1):114-21 (In Russ.). doi:10.21518/2307-1109-2017-1-114-121].

12. Lopes R.D., Rao M., Simon D.N., et al. Triple versus Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. Am J Med. 2016;129(6):592-9.e1. doi:10.1016/j.amjmed.2015.12.026.

13. Shakhmatova O.O., Panchenko Е.P. How to minimize the bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary interventions: lessons drawn from randomized trials and new clinical guidelines. Aterotromboz. 2018;(1):93-106. (In Russ.) doi:10.21518/2307-1109-2018-1-93-106.

14. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315. doi:10.1093/eurheartj/ehv320.

15. Gilyarov M.Yu., Konstantinova E.V. Antithrombotic therapy in patients with acute coronary syndrome and atrial fibrillation. Neotlozhnaya Kardiologiya. 2017(3):28-37. (In Russ.)

16. Halvorsen S., Storey R.F., Rocca B., et al. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J. 2016;38(19):1455-62. doi:10.1093/eurheartj/ehw454.

17. Pereverzeva K.G., Moseichuk K.A., Vorobyev A.N., et al. Dynamics of prescribing of oral anticoagulants to outpatients with atrial fibrillation during 2012-2016 according to the Registry of cardiovascular diseases Kardiologiya: Novosti, Mneniya, Obuchenie. 2017;1(12):44-7. (In Russ.)

18. Grajfer I.V., Kuvshinova L.E., Dolotovskaya P.V., et al. Risk of thromboembolic complications and antitrombotic therapy in in-patients with permanent and reccurent atrial fibrillation in real clinical practice. Rational Pharmacotherapy in Cardiology. 2012;8(5):675-80. (In Russ.). doi:10.20996/1819-6446-2012-8-5-675-680.

19. Sulimov V.A., Napalkov D.A., Sokolova A.A., et al. Anticoagulant therapy in everyday clinical practice: data of the retrospective cross-sectional study. Rational Pharmacotherapy in Cardiology. 2015;11(2):116-23. (In Russ.) doi:10.20996/1819-6446-2015-11-2-116-123.

20. Hohlova Yu.A., Aldohina E.O., Dudoladova Yu.I. Antithrombotic therapy of patients with atrial fibrillation in clinical practice Bulletin of the Smolensk State Medical Academy. 2016;15(3):24-30. (In Russ.)

21. Sokolov A. V., Rykalina E. B. Pharmacoepidemiological analysis of antithrombotic therapy in patients with persistent atrial fibrillation in the hospital. Bulletin of Medical Online Conferences. Science and Innovation. 2017;7(6):1276-7. (In Russ.)

22. Chernov A.A., Kleymenova E.V., Sychev D.A., et al. Physician’s Adherence to Clinical Guidelines for in-Hospital Anticoagulant Prescribing. Rational Pharmacotherapy in Cardiology. 2018;14(4):501-8. (In Russ.) doi:10.20996/1819-6446-2018-14-4-501-508].

23. Collet J.P., Aout M., Alantar A., et al. Real-life management ofdual antiplatelet therapy interruption: the REGINA survey. Arch Cardiovasc Dis. 2009;102:697-710. doi:10.1016/j.acvd.2009.08.009.

24. 2014 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation. Can J Cardiol. 2014;30:1114-30. doi:10.1016/j.jacc.2014.03.022.


For citation:


Pereverzeva K.G., Yakushin S.S., Pripadcheva A.E., Agaltsova N.P. Antithrombotic Therapy in Patients with Atrial Fibrillation after Myocardial Infarction: Clinical Guidelines and Actual Practice. Rational Pharmacotherapy in Cardiology. 2018;14(6):858-863. https://doi.org/10.20996/1819-6446-2018-14-6-858-863

Views: 201


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)